Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
Analysts Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) PT at $3.75
Luke Evnin Sells 24,678 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Luke Evnin Sells 24,962 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Luke Evnin Sells 18,568 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics Announces Pipeline and Business Updates
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics to Participate in the BIO International Convention
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates